The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Telemedicine is not reliable for assessing Centor criteria for patients with an acute sore throat, according to study findings.

The first-ever US FDA guidelines on lead in baby food are under fire from health experts who argue the limits are too lenient and fail to protect children from harmful exposure to toxic metals.

For immunocompromised individuals, antibody response to RSV vaccines is heterogeneous and about 40% do not seroconvert.

Adoption of the Acute Hospital Care at Home program is mainly limited to specific types of hospitals, according to study findings.

A Louisiana resident has died after being hospitalized with bird flu in December of last year, marking the first known US death from the virus.

The all-cause hospitalization rate at 28 days is high among adults with outpatient medically attended RSV infections.

Rates of pertussis in the US are surging, with more than 32,000 cases reported as of mid-December — about 6 times more than at this time last year and more than have been reported since 2014.

Zinplava (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the FDA’s drug shortages tracker.

The risk for STI reinfection and condom use at last sexual encounter vary by age and sexual orientation among people in the UK aged 16 to 24.

The Food and Drug Administration has approved the OraQuick® HIV Self-Test to include individuals 14 years of age and older.

The incidence of tularemia, a rare nationally notifiable zoonosis caused by Francisella tularensis, increased from 2001-2010 to 2011-2022.